April 9, 2020

Medical Devices Regulation: EU Commission proposes a one year postponement of the application date

On 3 April 2020, to prioritize the fight against the Covid-19 pandemic crisis, the European Commission adopted a proposal to (i) postpone the date of application of Regulation (EU) 2017/745 on medical devices (“MD Regulation”) (scheduled for 26 May 2020) by one year and (ii) deviate from the normal conformity assessment procedures of medical devices in cases of need and emergency.

A. One-year postponement of the date of application of the Regulation (EU) 2017/745 on medical devices

As is well known, the MD New Regulation will establish a new regulatory framework for the functioning of the internal market for medical devices. As of the date of application, the relevant national regulations (resulting from the transposition of the Directive 93/42/EEC) will be replaced by the MD New Regulation, which will regulate medical devices in a uniform manner throughout the European Union.

The outbreak of the pandemic just three months before the date of application definitively marked the need for a postponement that would be a relieve to Member States, health institutions, notified bodies and, in general, economic stakeholders that were already facing several challenges on different levels to implement in the time the MD Regulation and that now are under an enormous pressure due to the Covid-19 outbreak.

For instance, the process of “re-authorization” of the bodies responsible for certifying the conformity of medical devices to the new rules or the implementation of a unique European database for the registration of devices on the market were already experiencing significant delays. Due to a more complex process, only in Italy, 1 out of 11 notified bodies operating under the previous legal framework has been confirmed so far. Consequently, in several cases, economic operators were already having trouble to find notified bodies complying with the new rules to certify their devices as well as implementing the new measures. The pandemic would clearly make everything worst.

The Commission took note of the current situation by adopting this proposal, which now awaits final approval by the European Parliament and the Council in the coming days under an accelerated procedure.

The Commission’s decision aims at achieving the following objectives[1]:

  1. to avoid the risk that certain medical devices will not be available on the market due to delays in certification procedures according to the new standards required by the MD New Regulation; as the Covid-19 outbreak is increasing the demand for certain essential medical devices such as medical gloves, surgical masks, equipment for intensive care, etc., the Commission intends to expedite and facilitate the entire process and to avoid risks of potential shortages or delays in their availability caused by capacity constraints of public authorities or notified bodies; and
  2. to ensure that all resources and efforts of the industry are focused on fighting the pandemic, reducing “potential market disruption”, as said by Stella Kyriakides, Commissioner for Health and Food Safety, and ensuring a smooth transition to the new medical devices legal regime that nowadays would be rather difficult or perhaps impossible to achieve.

If the proposed postponement is enacted, Directive 93/42/EEC and the relevant European country specific implementing regulations would continue to be applied and all the transitional arrangements would also be extended for a further one-year period (by way of example, it would be allowed to keep on the market medical devices marketed under the previous legal framework, under certain conditions, until 25 May 2025 and not until 26 May 2024).

As final remark, we remind that this proposal will not affect the date of application of the Regulation (EU) 2017/746 on in vitro diagnostic medical devices, which will become applicable from 26 May 2022, as originally foreseen.

B. Derogation of conformity requirements at European level

The European Commission has also proposed a further amendment to the MD Regulation to provide the same Commission with the ability to adopt immediately (and not as of the date of application of the Regulation on 26 May 2020) derogations at European Union level from the requirements for the use of medical devices in order to address potential shortages of vital devices.

To this end, it is foreseen that the competent authority of a Member State may authorize the placing on its market of devices for which conformity assessment procedures have not been carried out but whose use is in the interest of public health. Following notification of the local measure by the Member State, the Commission may, in exceptional cases, extend the effects of such authorization to the territory of the whole European Union. This type of measures cannot be sufficiently achieved by each Member States on a stand-alone basis but can rather, by reason of its scale and effects, be better achieved at European Union level.

For instance, if the proposal is approved by Parliament and the Council, the Commission would have the ability to extend those emergency measures set forth under Italian law-decree 17 March 2020, n. 18 (“Decreto Cura Italia”) for Italy to the entire European Union, which allow the production, importation and placement on the market of surgical masks and personal protective equipment in derogation from the conformity provisions in force by submitting a self-certification (by which the operator shall simply declare to meet certain minimum requirements).

[1] Press release issued by the European Commission and available at the following address: https://ec.europa.eu/commission/presscorner/detail/en/ip_20_589.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

March 20, 2023
Today, Regulation (EU) 2023/607 extending the transitional provisions for the placing on the market and putting into service of certain medical devices and in vitro diagnostic medical device...
January 31, 2023
Clinical trials: Ministry of Health signed off on decrees that (i) reorganize ethics committees and coordinate their activities, (ii) determine the single tariff for the authorization proced...
December 19, 2022
On 13 December 2022, EMA, European Commission and HMA jointly adopted a recommendation paper on the introduction of decentralised elements in the conduct of Clinical Trials in the EU/EEA
September 21, 2022
Payback for medical devices: Decree quantifying the exceeding of the expenditure ceiling for medical devices at national and regional level for the years 2015, 2016, 2017 and 2018 published ...
September 1, 2022
The 2021 annual law for market and competition addressing, as to the healthcare sector, reimbursement of drugs, intermediate distribution, patent linkage and institutional accreditation of p...
Search by...
Follow us on
Follow us on